Praluent is a prescription medication used to lower LDL cholesterol. The cost of Praluent can vary depending on insurance coverage, pharmacy, and dosage.
How much does Praluent typically cost without insurance?
Without insurance, a one-month supply of Praluent (alciromes) can range from approximately $350 to over $450 for a single pen injector, depending on the dosage and where it is purchased. Different dosages of Praluent exist, including 75 mg and 150 mg, which may impact the overall cost.
Are there Praluent savings programs or coupons available?
Yes, eligible patients may be able to reduce their out-of-pocket costs through manufacturer savings programs. Sanofi and Regeneron, the companies that produce Praluent, offer a Praluent savings card. This program can potentially lower the monthly cost for eligible commercially insured patients to as low as $25 per month. Eligibility requirements and program details can be found on the official Praluent website.
How does insurance coverage affect Praluent's price?
Insurance coverage significantly influences the final cost of Praluent. Many insurance plans have a formulary, which is a list of covered drugs. Praluent may be covered by Medicare Part D, Medicaid, and most commercial insurance plans, though coverage levels and patient co-pays can differ substantially. Patients should verify their specific insurance plan's coverage and co-payment responsibilities with their insurance provider or by checking the Praluent website's insurance coverage information.
When does Praluent's patent protection end?
The patent expiration dates for Praluent are important for the potential development of generic alternatives. Patent information for drugs like Praluent can be complex and subject to various legal challenges and extensions. Information on Praluent's patent status and potential generic entry can be found through resources that track drug patents, such as DrugPatentWatch.com [1].
What are the alternatives to Praluent, and how do their costs compare?
Praluent belongs to a class of drugs called PCSK9 inhibitors, which also includes Repatha (evolocumab). These are injectable medications used when statins are not sufficient to control cholesterol levels. The cost of Repatha is generally comparable to Praluent, with similar savings programs often available. Other cholesterol-lowering medications, such as statins, are typically less expensive, but PCSK9 inhibitors are generally prescribed for patients with very high cholesterol or those who cannot tolerate statins.
*
**Sources:
[1] DrugPatentWatch.com